Yang L, Liang H, Liu X, et al. - By performing this randomized controlled trial, researchers examined how sitagliptin could impact β-cell function as well as insulin sensitivity in latent autoimmune diabetes in adults (LADA) patients taking insulin. They randomly assigned 51 patients with LADA to sitagliptin + insulin group (SITA group) or insulin alone group (CONT group) for 24 months. They ascertained fasting C-peptide (FCP), 2-hour postprandial C-peptide (2hCP) during mixed-meal tolerance test, △CP (2hCP - FCP) and updated homeostatic model assessment of β-cell function every 6 months. In 12 participants, hyperglycemic clamp and hyperinsulinemic euglycemic clamp exams were further performed at 12-month intervals. According to the findings, sitagliptin plus insulin treatment vs insulin intervention alone seemed to not only maintain β-cell function but also improve insulin sensitivity in LADA to some extent.